Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

The monoclonal antibody cetuximab, while not as effective as cisplatin, is often used as an alternative in these patients.

A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a ...

We all age. And while humanity's life expectancy has increased dramatically in the modern era, we still struggle with the ...

Researchers have developed a type of antibody that targets and delivers a drug package via the antibody itself, while ...

As part of an international collaboration, Fred Hutch scientists provided structural information that helped reveal how two ...

Illustration of a new form of precision medicine, an antibody, with the potential to treat several types of cancer.

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Israeli researchers and their colleagues from the United States developed an antibody-based treatment that empowers the ...

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...

Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion ...

In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical ...